JP2015523855A - Ａｐｏａ１及びａｂｃａ１発現を調節するための組成物及び方法 - Google Patents

Ａｐｏａ１及びａｂｃａ１発現を調節するための組成物及び方法 Download PDF

Info

Publication number
JP2015523855A
JP2015523855A JP2015512861A JP2015512861A JP2015523855A JP 2015523855 A JP2015523855 A JP 2015523855A JP 2015512861 A JP2015512861 A JP 2015512861A JP 2015512861 A JP2015512861 A JP 2015512861A JP 2015523855 A JP2015523855 A JP 2015523855A
Authority
JP
Japan
Prior art keywords
nucleotide
oligonucleotide
nucleotides
stranded oligonucleotide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015512861A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015523855A5 (enExample
Inventor
アーサー エム． クリーグ，
アーサー エム． クリーグ，
ロメシュ スブラマニアン，
ロメシュ スブラマニアン，
ジェイムズ マクスウィゲン，
ジェイムズ マクスウィゲン，
ジェニー ティー． リー，
ジェニー ティー． リー，
Original Assignee
ラナ セラピューティクス インコーポレイテッド
ラナ セラピューティクス インコーポレイテッド
ザ ジェネラル ホスピタル コーポレイション
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラナ セラピューティクス インコーポレイテッド, ラナ セラピューティクス インコーポレイテッド, ザ ジェネラル ホスピタル コーポレイション, ザ ジェネラル ホスピタル コーポレイション filed Critical ラナ セラピューティクス インコーポレイテッド
Publication of JP2015523855A publication Critical patent/JP2015523855A/ja
Publication of JP2015523855A5 publication Critical patent/JP2015523855A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015512861A 2012-05-16 2013-05-16 Ａｐｏａ１及びａｂｃａ１発現を調節するための組成物及び方法 Pending JP2015523855A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261647949P 2012-05-16 2012-05-16
US61/647,949 2012-05-16
US201361785778P 2013-03-14 2013-03-14
US61/785,778 2013-03-14
PCT/US2013/041455 WO2013173647A1 (en) 2012-05-16 2013-05-16 Compositions and methods for modulating apoa1 and abca1 expression

Publications (2)

Publication Number Publication Date
JP2015523855A true JP2015523855A (ja) 2015-08-20
JP2015523855A5 JP2015523855A5 (enExample) 2016-06-30

Family

ID=49584309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015512861A Pending JP2015523855A (ja) 2012-05-16 2013-05-16 Ａｐｏａ１及びａｂｃａ１発現を調節するための組成物及び方法

Country Status (9)

Country Link
US (1) US20150191722A1 (enExample)
EP (1) EP2849801A4 (enExample)
JP (1) JP2015523855A (enExample)
CN (1) CN104582737A (enExample)
AU (1) AU2013262658A1 (enExample)
BR (1) BR112014028645A2 (enExample)
CA (1) CA2873801A1 (enExample)
EA (1) EA201492119A1 (enExample)
WO (1) WO2013173647A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021514182A (ja) * 2018-02-09 2021-06-10 ジェネンテック， インコーポレイテッド Ｔｍｅｍ１０６ｂ発現を調節するためのオリゴヌクレオチド
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US12319913B2 (en) 2018-10-31 2025-06-03 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2638163T3 (en) 2010-11-12 2017-07-24 Massachusetts Gen Hospital POLYCOMB-ASSOCIATED NON-CODING RNAs
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
US9580708B2 (en) 2011-09-14 2017-02-28 Rana Therapeutics, Inc. Multimeric oligonucleotides compounds
EP2831232A4 (en) 2012-03-30 2015-11-04 Univ Washington METHODS OF MODULATING THE EXPRESSION OF TAU TO REDUCE THE STROKE AND MODIFY A NEURODEGENERATIVE SYMPTOM
EP2850185A4 (en) 2012-05-16 2015-12-30 Rana Therapeutics Inc COMPOSITIONS AND METHOD FOR MODULATING UTRN GENE EXPRESSION
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
BR112014028631A2 (pt) 2012-05-16 2017-10-17 Rana Therapeutics Inc composições e métodos para modulação da expressão da família de genes da hemoglobina
CA2873779A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating mecp2 expression
CN104583401A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节atp2a2表达的组合物和方法
KR20150030205A (ko) 2012-05-16 2015-03-19 라나 테라퓨틱스, 인크. Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
EP2895200B1 (en) 2012-09-14 2019-11-06 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
KR20150130430A (ko) 2013-03-14 2015-11-23 아이시스 파마수티컬즈 인코포레이티드 타우 발현을 조절하는 조성물 및 방법
JP6487913B2 (ja) * 2013-07-02 2019-03-20 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 成長ホルモン受容体のモジュレータ
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
WO2015023941A1 (en) * 2013-08-16 2015-02-19 Rana Therapeutics, Inc. Oligonucleotides targeting euchromatin regions of genes
WO2015162422A1 (en) * 2014-04-22 2015-10-29 Mina Therapeutics Limited Sarna compositions and methods of use
US9994855B2 (en) 2014-05-01 2018-06-12 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating growth hormone receptor expression
CA2966044A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
EP3256590A4 (en) * 2015-02-13 2018-10-03 Translate Bio Ma, Inc. Targeting oligonucleotides and uses thereof to modulate gene expression
WO2016130943A1 (en) 2015-02-13 2016-08-18 Rana Therapeutics, Inc. Hybrid oligonucleotides and uses thereof
US10900036B2 (en) 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム
US11447773B2 (en) 2017-09-08 2022-09-20 Mina Therapeutics Limited Stabilized HNF4A saRNA compositions and methods of use
EP4219715A3 (en) 2017-09-08 2023-09-06 MiNA Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
DK3700570T3 (da) * 2017-10-23 2025-03-31 Stoke Therapeutics Inc Antisense-oligomerer til behandling af ikke-sense medieret rna henfald baserede tilstande og sygdomme
SG11202012759XA (en) 2018-07-03 2021-01-28 Hoffmann La Roche Oligonucleotides for modulating tau expression
KR102597727B1 (ko) 2018-09-04 2023-11-06 프로토타입 앤드 프로덕션 시스템스, 인코포레이티드 프린트 모듈 캡핑 스테이션
JP2022545101A (ja) 2019-08-19 2022-10-25 ミナ セラピューティクス リミテッド オリゴヌクレオチドコンジュゲート組成物および使用方法
US12194057B2 (en) * 2020-12-17 2025-01-14 Washington University NXTAR-derived oligonucleotides and uses thereof
US12478949B2 (en) 2022-08-26 2025-11-25 Waters Technologies Corporation Composite particles with non-porous hybrid organic-inorganic material

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008044958A (ja) * 2000-11-20 2008-02-28 Board Of Trustees Of The Univ Of Illinois 膜スカホールドタンパク質

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2367955C (en) * 1999-03-15 2009-05-19 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
WO2002103015A2 (en) * 2001-06-14 2002-12-27 Active Pass Pharmaceuticals, Inc. Abca10 transporter
US7259150B2 (en) * 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US20050265927A1 (en) * 2004-05-17 2005-12-01 Yale University Intranasal delivery of nucleic acid molecules
WO2008103761A2 (en) * 2007-02-20 2008-08-28 Sequenom, Inc. Methods and compositions for cancer diagnosis and treatment based on nucleic acid methylation
CA2739464C (en) * 2008-10-03 2020-03-31 Opko Curna, Llc Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
GB0821457D0 (en) * 2008-11-24 2008-12-31 Trillion Genomics Ltd Oligonucleotides
KR101835889B1 (ko) * 2009-05-06 2018-03-08 큐알엔에이, 인크. 지질 수송 및 대사 유전자에 대한 천연 안티센스 전사체의 억제에 의해 지질 수송 및 대사 유전자 관련된 질환의 치료
WO2012087983A1 (en) * 2010-12-20 2012-06-28 The General Hospital Corporation Polycomb-associated non-coding rnas
WO2013173652A1 (en) * 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008044958A (ja) * 2000-11-20 2008-02-28 Board Of Trustees Of The Univ Of Illinois 膜スカホールドタンパク質

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM. LETT., vol. 22, JPN6017009553, 2012, pages 2963 - 2967, ISSN: 0003521140 *
ELECTROPHORESIS, vol. 24, JPN6017009552, 2003, pages 3748 - 3754, ISSN: 0003521139 *
J. CLIN. INVEST., vol. 116, no. 12, JPN6017009555, 2006, pages 3090 - 3100, ISSN: 0003521141 *
MOL. CELL, vol. 40, JPN6017009567, 2010, pages 939 - 953, ISSN: 0003521146 *
MOL. CELL. BIOL., vol. 28, no. 20, JPN6017009560, 2008, pages 6473 - 6482, ISSN: 0003521143 *
PLOS ONE, vol. Vol.7, Issue 5, JPN6017009563, 2012, pages 36365, ISSN: 0003521144 *
PROC. NATL. ACAD. SCI., vol. 106, no. 28, JPN6017009564, 2009, pages 11667 - 11672, ISSN: 0003521145 *
中尾光善: ""エピジェネティクス機構による遺伝子クラスター制御および細胞病態"", 上原記念生命科学財団研究報告集, vol. 23, JPN6017009557, 2003, pages 54, ISSN: 0003521142 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US12371693B2 (en) 2016-11-01 2025-07-29 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
JP2021514182A (ja) * 2018-02-09 2021-06-10 ジェネンテック， インコーポレイテッド Ｔｍｅｍ１０６ｂ発現を調節するためのオリゴヌクレオチド
JP7281474B2 (ja) 2018-02-09 2023-05-25 ジェネンテック， インコーポレイテッド Ｔｍｅｍ１０６ｂ発現を調節するためのオリゴヌクレオチド
US12319913B2 (en) 2018-10-31 2025-06-03 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer

Also Published As

Publication number Publication date
EP2849801A4 (en) 2016-05-25
EA201492119A1 (ru) 2015-05-29
AU2013262658A1 (en) 2015-01-22
CN104582737A (zh) 2015-04-29
EP2849801A1 (en) 2015-03-25
WO2013173647A1 (en) 2013-11-21
US20150191722A1 (en) 2015-07-09
CA2873801A1 (en) 2013-11-21
BR112014028645A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
JP2015523855A (ja) Ａｐｏａ１及びａｂｃａ１発現を調節するための組成物及び方法
JP2015518712A (ja) Ｍｅｃｐ２発現を調節するための組成物及び方法
JP2015518713A (ja) Ｕｔｒｎ発現を調節するための組成物及び方法
JP2015523853A (ja) Ａｔｐ２ａ２発現を調節するための組成物及び方法
EP2850186B1 (en) Compositions and methods for modulating smn gene family expression
JP2015518710A (ja) ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法
JP2015519057A (ja) Ｐｔｅｎ発現を調節するための組成物及び方法
JP2015518711A (ja) Ｂｄｎｆ発現を調節するための組成物及び方法
US10041074B2 (en) Euchromatic region targeting methods for modulating gene expression
US20160201064A1 (en) Compositions and methods for modulating expression of frataxin
JP6837963B2 (ja) Ｍｉｒ−２９模倣物およびその使用
JP2016521556A (ja) Ｆｏｘｐ３発現を調節するための組成物及び方法
US20150225722A1 (en) Methods for selective targeting of heterochromatin forming non-coding rna
US20150232836A1 (en) Compositions and methods for modulating gene expression
US20160201063A1 (en) Epigenetic regulators of frataxin
AU2014306416A9 (en) Compositions and methods for modulating RNA
JP2016534035A (ja) 筋萎縮性側索硬化症を治療するための組成物及び方法
US10758558B2 (en) Hybrid oligonucleotides and uses thereof
JP2016522674A (ja) 遺伝子発現を調節するための組成物及び方法
JP2015518714A (ja) 遺伝子発現を調節するための組成物及び方法
JP2014527819A5 (enExample)
AU2022203361A1 (en) Compositions and methods for modulating RNA
US20180030452A1 (en) Targeting oligonucleotides and uses thereof to modulate gene expression
US20220056443A1 (en) Metabolic benefits of short mir-22 mirna antagomir therapies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170321

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171013